How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics

About this episode

Jonathan Sporn discusses the development of next-gen psychedelic medicines and a significant partnership with AbbVie.

Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B. In this episode, we discuss: • Why Gilgamesh is building psychedelic medicines the way large pharma would • The thesis behind short-acting psychedelics and why long-duration trips are impractical...

People in this episode

Hosts: Greg Kubin, Matias Serebrinsky

Guest: Jonathan Sporn

Topics covered

• psychedelic medicines
• pharmaceutical partnerships
• clinical use
• short-acting psychedelics
• long-duration trips

Keywords

• psychedelics
• Gilgamesh Pharma
• AbbVie
• clinical use
• pharmaceuticals
• short-acting
• long-duration

Mentioned in this episode

Organizations: Gilgamesh Pharma, AbbVie

More episodes of Business Trip

• Brain Organoids: from Space to AI with Alysson Muotri · May 14, 2026 · 34 min
• Inside Philanthropy’s Role in Mental & Brain Health · January 27, 2026 · 42 min
• Rick Perry on paving the way for Ibogaine in America · December 19, 2025 · 40 min
• Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute · November 24, 2025 · 49 min
• AI and the future of therapy with Luis Voloch of Jimini Health · October 16, 2025 · 38 min
• Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka · September 23, 2025 · 1h 33m